Background
Chlamydia trachomatis is a multifaceted, asymptomatic, most prevalent sexually transmitted pathogen worldwide. Due to lack of specific diagnostic methods for C. trachomatis in Spondyloarthropathy (SpA) patients, this pathogen is under diagnosed and under estimated in various countries including India. We aimed to estimate circulatory antibodies to chlamydial heat shock protein-60 (chsp60) IgG/ anti C. trachomatis IgA and evaluate their clinical significance in SpA patients.
Methods
In this case control study, serum from 60 arthritic patients comprising of Reactive Arthritis (ReA), undifferentiated SpA, Rheumatoid Arthritis (RA) and Osteoarthritis (OA) was collected for detection of anti chsp60 IgG and anti C. trachomatis IgA antibodies by using commercial ELISA kits. Cut-off indices (COI) of infected SpA patients were correlated with clinical data.
Anzeige
Results
Overall, 12/ 30 (40.0%) SpA patients, viz.: ReA/uSpA, were found positive for either circulatory chsp60 IgG or anti C. trachomatis IgA antibody (p value < 0.009 versus RA/ OA). 23.3% (7/ 30) SpA patients and 3.3 % (1/30) RA/OA control patients were found to be positive for circulatory chsp60 IgG antibodies. 16.6% (5/ 30) patients found positive for anti C. trachomatis IgA antibodies; however, none of the controls was infected. COI, age and disease duration in chsp60-positive SpA patients showed significant difference in median values (Kruskal-Wallis test; p value < 0.0001) while there was no such relation to anti C. trachomatis IgA.
Conclusion
Overall findings indicate an active/chronic C. trachomatis infection in SpA patients. The study also suggests usefulness of chsp60 serology to facilitate better clinical management of patients.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.